The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Open accessAbstract
Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies using TβRI small molecule inhibitors confirmed attenuation of metastasis in various carcinoma types325.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [325]
In the citing paper
“TGF-β inhibition as monotherapy, using neutralizing antibodies, ligand traps or receptor kinase inhibitors, has seen some success in mouse models of carcinomas, primarily in reducing metastatic spread rather than reducing growth of the primary tumor325 (Table 1).”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [325]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Cited by
Sorted by citations
Items 301–400 of 1,001
Papadatos-Pastos, D., Yuan, W., Pal, A., Crespo, M., Ferreira, A., Gürel, B., Prout, T., Ameratunga, M., Chénard-Poirier, M., Curcean, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004495 · Cited by 60
Caii, W., Wu, X. H., Guo, K., Chen, Y., Shi, Y., & Chen, J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03724-3 · Cited by 62
“Disease progression was judged by the individual’s overall clinical condition and the response evaluation criteria in solid tumors [23, 24], derived from imaging evaluations.”
MethodKawazoe, A., Yamaguchi, K., Yasui, H., Negoro, Y., Azuma, M., Amagai, K., Hara, H., Baba, H., Tsuda, M., Hosaka, H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.002 · Cited by 62
Ragoonanan, D. S., Khazal, S. J., Abdel‐Azim, H., McCall, D. C., Cuglievan, B., Tambaro, F. P., Ahmad, A. H., Rowan, C. M., Gutiérrez, C., Schadler, K., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00474-4 · Cited by 62
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
Dercle, L., Sun, S. H., Seban, R., Mekki, A., Sun, R., Tselikas, L., Hans, S., Bernard‐Tessier, A., Bouvier, F. M., Aide, N., et al. (2022) · Radiology · doi:10.1148/radiol.210518 · Cited by 61
Self-citationIshihara, M., Nishida, Y., Kitano, S., Kawai, A., Muraoka, D., Momose, F., Harada, N., Miyahara, Y., Seo, N., Hattori, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34453 · Cited by 61
Kulkarni, A. V., Tevethia, H. V., Kumar, K., Premkumar, M., Muttaiah, M. D., Hiraoka, A., Hatanaka, T., Tada, T., Kumada, T., Kakizaki, S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102179 · Cited by 61
Raverot, G., Burman, P., Abreu, A. P., Heaney, A. P., van Hulsteijn, L. T., Lin, A. L., Marcus, H. J., McCormack, A. I., Minniti, G., Petersenn, S., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf100 · Cited by 74
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., et al. (2025) · Liver Cancer · doi:10.1159/000546574 · Cited by 78
Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2229-6 · Cited by 61
Beer, L., Hochmair, M. J., Haug, A. R., Schwabel, B., Kifjak, D., Wadsak, W., Fuereder, T., Fabikan, H., Fazekas, A. S., Schwab, S., et al. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002603 · Cited by 64
Solinas, C., Porcu, M., Hlavatá, Z., Silva, P. D., Puzzoni, M., Willard-Gallo, K., Scartozzi, M., & Saba, L. (2017) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2017.09.017 · Cited by 57
Fessas, P., Kaseb, A. O., Wang, Y., Saeed, A., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001033 · Cited by 60
Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective
Lang, D., Wahl, G., Poier-Fabian, N., Graf, S., Kiesl, D., Lamprecht, B., & Gabriel, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113483 · Cited by 60
Botticelli, A., Zizzari, I. G., Scagnoli, S., Pomati, G., Strigari, L., Cirillo, A., Cerbelli, B., Filippo, A. D., Napoletano, C., Scirocchi, F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070651 · Cited by 60
Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review
Reginelli, A., Nardone, V., Giacobbe, G., Belfiore, M. P., Grassi, R., Schettino, F., Canto, M. T. D., Grassi, R., & Cappabianca, S. (2021) · Diagnostics · doi:10.3390/diagnostics11101796 · Cited by 60
Nguyen, L. T. H., Zhang, J., Rima, X. Y., Wang, X., Kwak, K. J., Okimoto, T., Amann, J. M., Yoon, M. J., Shukuya, T., Chiang, C., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12258 · Cited by 56
Tumor response assessment on imaging following immunotherapy
Berz, A. M., Dromain, C., Violi, N. V., Boughdad, S., & Durán, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982983 · Cited by 62
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25404 · Cited by 60
Kinget, L., Naulaerts, S., Govaerts, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Dubroja, N., Shankar, G., Bosisio, F. M., Roussel, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02978-9 · Cited by 60
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis, M., Duruisseaux, M., Brevet, M., & Dumontet, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00492 · Cited by 59
Simonaggio, A., Elaidi, R., Fournier, L. S., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthélémy, P., Thibault, C., Tartour, É., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02637-1 · Cited by 62
Elkassem, A. M. A., Allen, B. C., Sharbidre, K., Rais‐Bahrami, S., & Smith, A. D. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25493 · Cited by 58
Immunotherapy for pancreatic cancer
Yoon, J. H., Jung, Y.-J., & Moon, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2969 · Cited by 58
Fournier, L., de Geus-Oei, L. D., Regge, D., Oprea-Lager, D., D'Anastasi, M., Bidaut, L., Bäuerle, T., Lopci, E., Cappello, G., Lecouvet, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800547 · Cited by 49
Self-citationPagadala, M. S., Sears, T. J., Wu, V. H., Pérez‐Guijarro, E., Kim, H., Castro, A., Talwar, J. V., González-Colín, C., Cao, S., Schmiedel, B. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38271-5 · Cited by 54
“Response phenotypes were determined from iRECIST criteria 170 .”
Ratovomanana, T., Nicolle, R., Cohen, R., Diehl, A., Siret, A., Letourneur, Q., Buhard, O., Perrier, A., Guillerm, E., Coulet, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.010 · Cited by 59
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Schroeder, T., Martens, T., Fransecky, L. R., Valerius, T., Schub, N., Pott, C., Baldus, C. D., & Stölzel, F. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07576-4 · Cited by 58
“…(e.g. here: “my favourite color is green”, in German: “Meine Lieblingsfarbe ist grün”) pseudoprogression benefits from established toxicity criteria such as RECIST, LUGANO and LYRIC [41], CAR-T cell therapy has seen only a few reported cases of transient progression followed by regression [42, 43].”
Unlocking the Power of Artificial Intelligence and Big Data in Medicine
Lovis, C. (2019) · Journal of Medical Internet Research · doi:10.2196/16607 · Cited by 61
Galot, R., Tourneau, C. L., Saâda-Bouzid, E., Daste, A., Even, C., Debruyne, P. R., Henry, S., Zanetta, S., Rutten, A., Licitra, L. F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.003 · Cited by 58
Yang, J. C., Han, B., Jimenez, E. D. L. M., Lee, J.-S., Koralewski, P., Karadurmuş, N., Sugawara, S., Livi, L., Basappa, N. S., Quantin, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.023 · Cited by 57
Immunotherapy in Non–Small Cell Lung Cancer Treatment
Carter, B. W., Halpenny, D. F., Ginsberg, M. S., Papadimitrakopoulou, V. A., & de Groot, P. M. (2017) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000291 · Cited by 57
Nie, R., Chen, F., Yuan, S., Luo, Y.-S., Chen, S., Chen, Y., Chen, X., Chen, Y.-B., Li, Y., & Zhou, Z. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.011 · Cited by 59
Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M. A., Lai, Q., Sandri, G. B. L., Melandro, F., Morisco, F., et al. (2019) · Cancers · doi:10.3390/cancers11111689 · Cited by 57
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
Li, J., Kan, H., Zhao, L., Sun, Z., & Bai, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922028 · Cited by 58
Deschênes‐Simard, X., Richard, C., Galland, L., Blais, F., Desîlets, A., Malo, J., Cvetkovic, L., Belkaïd, W., Elkrief, A., Gagné, A., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.018 · Cited by 57
Al-Showbaki, L., Wilson, B. E., Tamimi, F., Moltó, C., Mittal, A., Cescon, D. W., & Amir, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005854 · Cited by 56
Hochmair, M. J., Schwab, S., Burghuber, O. C., Krenbek, D., & Prosch, H. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.020 · Cited by 56
Guaraldi, F., Selva, R. L., Samà, M. T., D’Angelo, V., Gori, D., Fava, P., Fierro, M. T., Savoia, P., & Arvat, E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0772-1 · Cited by 56
Chia, S., Bedard, P. L., Hilton, J. F., Amir, E., Gelmon, K. A., Goodwin, R. A., Villa, D. R., Cabanero, M., Tu, D., Tsao, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0321 · Cited by 56
Self-citationImmunotherapy-related adverse effects on 18F-FDG PET/CT imaging
Gandy, N., Arshad, M., Wallitt, K. L., Dubash, S., Khan, S., & Barwick, T. D. (2020) · British Journal of Radiology · doi:10.1259/bjr.20190832 · Cited by 55
Merlino, D. J., Johnson, J. M., Tuluc, M., Gargano, S., Stapp, R., Harshyne, L. A., Leiby, B. E., Flanders, A. E., Zinner, R., Axelrod, R. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566315 · Cited by 56
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Islam, M. R., Islam, M. R., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 55
Challenges in assessing solid tumor responses to immunotherapy
Chai, L. F., Prince, E. A., Pillarisetty, V. G., & Katz, S. C. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0155-1 · Cited by 56
Butner, J. D., Elganainy, D., Wang, C. X., Wang, Z., Chen, S., Esnaola, N. F., Pasqualini, R., Arap, W., Hong, D. S., Welsh, J. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6298 · Cited by 53
MR cell size imaging with temporal diffusion spectroscopy
Jiang, X., Li, H., Devan, S. P., Gore, J. C., & Xu, J. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.12.010 · Cited by 54
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Amato, O., Giannopoulou, N., & Ignatiadis, M. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00626-6 · Cited by 64
“While RECIST evaluation criteria are tumor agnostic and to some extent treatment agnostic 80 (with the exception of immunotherapy 81 ), it is likely that ctDNA dynamics could be tumor and treatment dependent.”
BackgroundHuang, Z., Karaboué, A., Zeng, L., Lecoeuvre, A., Zhang, L., Li, X., Qin, H., Danino, G., Yang, F., Malin, M.-S., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105607 · Cited by 54
Diseases of the Abdomen and Pelvis 2018-2021
Hodler, J., Huch, R., & von Schulthess, G. K. (2018) · IDKD Springer series · doi:10.1007/978-3-319-75019-4 · Cited by 56
Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review
Bisschop, K., de Heer, E. C., Brouwers, A. H., Hospers, G. A. P., & Jalving, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103044 · Cited by 56
Li, L., Wang, Y., Shi, W., Zhu, M., Liu, Z., Luo, N., Zeng, Y., & He, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2632 · Cited by 54
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 55
Geng, Q., Li, L., Shen, Z., Zheng, Y., Wang, L., Xue, R., Xue, W., Peng, M., & Zhao, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02132-7 · Cited by 55
“According to the iRECIST evaluation criteria, the LUAD patients were divided into two groups: the resistance group (n= 10) and the sensitive group (n= 10) [21].”
MethodFerrarotto, R., de Sousa, L. G., Feng, L., Mott, F. E., Blumenschein, G. R., Altan, M., Bell, D., Bonini, F., Li, K., Marques-Piubelli, M. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02221 · Cited by 57
Yu, J., Xiao, B.-Y., Li, D.-D., Jiang, W., Ding, Y., Wu, X.-J., Zhang, R.-X., Lin, J., Wang, W., Han, K., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00203-1 · Cited by 53
Giannicola, R., D’Arrigo, G., Botta, C., Agostino, R. M., Medico, P. D., Falzea, A. C., Barbieri, V., Staropoli, N., Giudice, T. D., Pastina, P., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1859 · Cited by 53
Castello, A., Toschi, L., Rossi, S., Mazziotti, E., & Lopci, E. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03150-9 · Cited by 53
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 53
Lau, A., Yang, W., Li, K. Y., & Su, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102984 · Cited by 53
Seban, R., Assié, J., Leprieur, E. G., Massiani, M.-A., Bonardel, G., CHOUAID, C., Deleval, N., Richard, C., Mezquita, L., Girard, N., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.024 · Cited by 53
Bergman, P. J. (2019) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2019.04.010 · Cited by 56
Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
Kurman, J. S., & Murgu, S. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.79 · Cited by 52
Kok, P., Cho, D., Yoon, W.-H., Ritchie, G. E., Marschner, I. C., Lord, S. J., Friedlander, M. L., Simes, J. R., & Lee, C. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11809 · Cited by 52
Majem, M., Hernández, J. H., Hernándo, F., de Dios, N. R., Sotoca, A., Trujillo-Reyes, J. C., Vollmer, I., Delgado-Bolton, R., & Provencio, M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02134-7 · Cited by 52
Rossi, G., Bauckneht, M., Genova, C., Rijavec, E., Biello, F., Mennella, S., Bello, M. G. D., Cittadini, G., Bruzzi, P., Piva, R., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233056 · Cited by 52
Iravani, A., & Hicks, R. J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234278 · Cited by 53
Xu, Y., Li, H., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642883 · Cited by 54
Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers‐Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08018-w · Cited by 53
Self-citationEze, C., Schmidt-Hegemann, N.-S., Sawicki, L. M., Kirchner, J., Roengvoraphoj, O., Käsmann, L., Mittlmeier, L. M., Kunz, W. G., Tufman, A., Dinkel, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05211-8 · Cited by 54
Deciphering radiological stable disease to immune checkpoint inhibitors
Luo, J., Wu, S., Rizvi, H. A., Zhang, Q., Egger, J. V., Osorio, J. C., Schoenfeld, A. J., Plodkowski, A. J., Ginsberg, M. S., Callahan, M. K., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.450 · Cited by 52
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Luke, J. J., Pinato, D. J., Juric, D., LoRusso, P. M., Hosein, P. J., Desai, A. M., Haddad, R. I., de Miguel, M., Cervantes, A. M. R., Kim, W. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010511 · Cited by 51
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
“To distinguish pseudoprogression from true progression, follow-up imaging after 4–8 weeks is required in order to assess whether the tumour stabilizes or shrinks (thus differentiating immune-unconfirmed progressive disease (iUPD) from immune-confirmed progressive disease (iCPD)) 144 .”
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., DeFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics
Barabino, E., Rossi, G., Pamparino, S., Fiannacca, M., Caprioli, S., Fedeli, A., Zullo, L., Vagge, S., Cittadini, G., & Genova, C. (2022) · Cancers · doi:10.3390/cancers14020350 · Cited by 50
Aujay, G., Etchegaray, C., Blanc, J., Lapuyade, B., Papadopoulos, P., Pey, M.-A., Bordenave, L., Trillaud, H., Saut, O., & Pinaquy, J. (2022) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2022.01.009 · Cited by 50
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese, T., Tamma, R., & Ribatti, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871085 · Cited by 54
Makker, V., Aghajanian, C. A., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., Messing, M. J., Dutta, L., Dutcus, C. E., Huang, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01021 · Cited by 54
Vrankar, M., & Unk, M. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0037 · Cited by 50
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
Correale, P., Saladino, R. E., Giannarelli, D., Sergi, A., Mazzei, M. A., Bianco, G., Giannicola, R., Iuliano, E., Forte, I. M., Calandruccio, N. D., et al. (2020) · Cells · doi:10.3390/cells9091964 · Cited by 50
Mattes, M. D., Eubank, T. D., Almubarak, M., Wen, S., Marano, G., Jacobson, G. M., & Ma, P. C. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.012 · Cited by 48
Xie, Y., Lin, J., Zhang, N., Wang, X., Wang, P., Peng, S., Li, J., Wu, Y., Huang, Y., Zhuang, Z., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7071 · Cited by 49
Tan, W., Yang, M. W., Yang, H., Zhou, F., & Shen, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174435 · Cited by 49
The potential of breath analysis to improve outcome for patients with lung cancer
Antoniou, S., Gaude, E., Ruparel, M., van der Schee, M. P., Janes, S. M., & Rintoul, R. C. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/ab0bee · Cited by 49
Jain, R., Handorf, E. A., Khare, V., Blau, M., Chertock, Y., & Hall, M. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0289 · Cited by 51
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 49
Brendlin, A., Peisen, F., Almansour, H., Afat, S., Eigentler, T., Amaral, T. M. S., Faby, S., Calvarons, A. F., Nikolaou, K., & Othman, A. E. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003261 · Cited by 47
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub2 · Cited by 51
Laurie, S. A., Banerji, S. O., Blais, N., Brule, S. Y., Cheema, P. K., Cheung, P., Daaboul, N., Hao, D., Hirsh, V., Juergens, R. A., et al. (2019) · Current Oncology · doi:10.3747/co.26.4116 · Cited by 48
Imaging CAR T-cell kinetics in solid tumors: Translational implications
Skovgard, M. S., Hocine, H. R., Saini, J. K., Moroz, M. A., Bellis, R. Y., Banerjee, S., Morello, A., Ponomarev, V., Villena‐Vargas, J., & Adusumilli, P. S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.006 · Cited by 48
Chicas-Sett, R., Zafra, J., Rodríguez‐Abreu, D., Castilla-Martinez, J., Benítez, G., Salas-Salas, B., Hernández, S., Lloret, M., Onieva, J. L., Barragán, I., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.013 · Cited by 48
Nishio, M., Takahashi, T., Yoshioka, H., Nakagawa, K., Fukuhara, T., Yamada, K., Ichiki, M., Tanaka, H., Seto, T., Sakai, H., et al. (2019) · Cancer Science · doi:10.1111/cas.13932 · Cited by 48
Ricciuti, B., Genova, C., Bassanelli, M., Giglio, A. D., Brambilla, M., Metro, G., Baglivo, S., Bello, M. G. D., Ceribelli, A., Grossi, F., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.001 · Cited by 48
Liu, D.-X., Li, D., He, W., Ke, C., Wu, J., Tang, J.-H., Kong, L.-H., Li, Y., Sui, Q., Xiao, B.-Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1711650 · Cited by 49
Joseph, A., Simonaggio, A., Stoclin, A., Vieillard‐Baron, A., Géri, G., Oudard, S. M., Michot, J., Lambotte, O., Azoulay, É., & Lemiale, V. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00761-w · Cited by 49
Liberini, V., Laudicella, R., Capozza, M., Huellner, M. W., Burger, I. A., Baldari, S., Terreno, E., & Deandreis, D. (2021) · Molecules · doi:10.3390/molecules26082201 · Cited by 48
van de Donk, P. P., Wind, T. T., Hooiveld-Noeken, J. S., van der Veen, E. L., Glaudemans, A. W. J. M., Diepstra, A., Jalving, M., de Vries, E. G. E., de Vries, E. F. J., & Hospers, G. A. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05407-y · Cited by 48
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response
Wu, M., Zhang, Y., Zhang, Y., Liu, Y., Wu, M., & Ye, Z. (2019) · Radiology Imaging Cancer · doi:10.1148/rycan.2019190031 · Cited by 47
Das, S., Camphausen, K. A., & Shankavaram, U. T. (2020) · Cancers · doi:10.3390/cancers12092476 · Cited by 47
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 48
Starzer, A. M., Berghoff, A. S., Hamacher, R., Tomasich, E., Feldmann, K., Hatziioannou, T., Traint, S., Lamm, W. W., Noebauer-Huhmann, I. M., Furtner, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001458 · Cited by 47
Metadata
- Authors
- Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., Hodi, F. S., Therasse, P., Hoekstra, O. S., Shankar, L. K., Wolchok, J. D., Ballinger, M., Caramella, C., & de Vries, E. G. E.
- Affiliations
- Queen's University (CA)
- European Organisation for Research and Treatment of Cancer (BE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- NewYork–Presbyterian Hospital (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Harvard University (US)
- Institut de Recherches Internationales Servier (France) (FR)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Memorial Sloan Kettering Cancer Center (US)
- Genentech (US)
- Institut Gustave Roussy (FR)
- Corresponding author
- Seymour, Lesley
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 18
- Issue
- 3
- Pages
- e143-e152
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5648544
- OpenAlex
- W2592144107
- Cited by
- 2,472
- References
- 37
- Citations by year
- 2026: 264 · 2025: 267 · 2024: 319 · 2023: 305 · 2022: 270 · 2021: 308 · 2020: 304 · 2019: 223 · 2018: 146 · 2017: 62
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2019-05-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Cancer Institute (U10CA011488, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- iRECIST, cancer immunotherapy, response evaluation criteria, disease progression, immunomodulators, clinical trial data collection, data warehouse
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Practice Guidelines as Topic, Disease Progression, Tumor Burden, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
